Home Journal Club	FAQ My Amedeo About Tranquillis Services	Flying Publisher
	Books, Journals, Podcasts, Weekly Updates, by Amedeo

Ovarian Neoplasms

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 53 articles: HTML format Text format

Single Articles

March 2010
1. SATOH T , Hatae M, Watanabe Y, Yaegashi N, et al
   Outcomes of Fertility-Sparing Surgery for Stage I Epithelial Ovarian Cancer: A Proposal for Patient Selection.
   J Clin Oncol. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
2. DU BOIS A , Reuss A, Harter P, Pujade-Lauraine E, et al
   Potential Role of Lymphadenectomy in Advanced Ovarian Cancer: A Combined Exploratory Analysis of Three Prospectively Randomized Phase III Multicenter Trials.
   J Clin Oncol. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   January 2010
3. KURIAN AW , Sigal BM, Plevritis SK
   Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers.
   J Clin Oncol. 2010;28:222-31.
   PubMed     Text format     Related articles    Abstract available
   
   
   
4. DE GEEST K , Blessing JA, Morris RT, Yamada SD, et al
   Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.
   J Clin Oncol. 2010;28:149-53.
   PubMed     Text format     Related articles    Abstract available
   
   
   
5. PENSON RT , Dizon DS, Cannistra SA, Roche MR, et al
   Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.
   J Clin Oncol. 2010;28:154-9.
   PubMed     Text format     Related articles    Abstract available
   
   
   December 2009
6. OKTAY K , Kim JY, Barad D, Babayev SN, et al
   Association of BRCA1 Mutations With Occult Primary Ovarian Insufficiency: A Possible Explanation for the Link Between Infertility and Breast/Ovarian Cancer Risks.
   J Clin Oncol. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   November 2009
7. SINGHAL MK , Krishnan V, Singh S, Kumar R, et al
   Isolated Ovarian Relapse in a 68-Year-Old Woman With Acute Lymphoblastic Leukemia.
   J Clin Oncol. 2009.
   PubMed     Text format     Related articles   
   
   
   
8. MATULONIS UA , Berlin S, Ivy P, Tyburski K, et al
   Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
   J Clin Oncol. 2009;27:5601-6.
   PubMed     Text format     Related articles    Abstract available
   
   
   
9. MAKHIJA S , Amler LC, Glenn D, Ueland FR, et al
   Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer.
   J Clin Oncol. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   October 2009
10. KWON JS , Daniels MS, Sun CC, Lu KH, et al
    Preventing Future Cancers by Testing Women With Ovarian Cancer for BRCA Mutations.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    September 2009
11. MATEI D , Miller AM, Monahan P, Gershenson D, et al
    Chronic physical effects and health care utilization in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group study.
    J Clin Oncol. 2009;27:4142-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    August 2009
12. PECORELLI S , Favalli G, Gadducci A, Katsaros D, et al
    Phase III Trial of Observation Versus Six Courses of Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer in Complete Response After Six Courses of Paclitaxel/Platinum-Based Chemotherapy: Final Results of the After-6 Protocol 1.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
13. MCGUIRE WP
    Maintenance Therapy for Ovarian Cancer: Of Helsinki and Hippocrates.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles   
    
    
    July 2009
14. ZIGHELBOIM I , Schmidt AP, Gao F, Thaker PH, et al
    ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes.
    J Clin Oncol. 2009;27:3091-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
15. TEN BOKKEL HUININK WW , Sufliarsky J, Smit WM, Spanik S, et al
    Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.
    J Clin Oncol. 2009;27:3097-103.
    PubMed     Text format     Related articles    Abstract available
    
    
    June 2009
16. MILLER DS , Blessing JA, Krasner CN, Mannel RS, et al
    Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.
    J Clin Oncol. 2009;27:2686-91.
    PubMed     Text format     Related articles    Abstract available
    
    
    March 2009
17. TENERIELLO MG , Tseng PC, Crozier M, Encarnacion C, et al
    Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
    J Clin Oncol. 2009;27:1426-31.
    PubMed     Text format     Related articles    Abstract available
    
    
    
18. RUBINSTEIN Y , Dashkovsky I, Cozacov C, Hadary A, et al
    Pseudo meigs' syndrome secondary to colorectal adenocarcinoma metastasis to the ovaries.
    J Clin Oncol. 2009;27:1334-6.
    PubMed     Text format     Related articles   
    
    
    February 2009
19. BOOKMAN MA , Brady MF, McGuire WP, Harper PG, et al
    Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
20. HOSKINS PJ
    Triple Cytotoxic Therapy for Advanced Ovarian Cancer: A Failed Application, Not a Failed Strategy.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles   
    
    
    January 2009
21. STENSHEIM H , Moller B, van Dijk T, Fossa SD, et al
    Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study.
    J Clin Oncol. 2009;27:45-51.
    PubMed     Text format     Related articles    Abstract available
    
    
    December 2008
22. BEREK J , Taylor P, McGuire W, Smith LM, et al
    Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer.
    J Clin Oncol. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    November 2008
23. SPEARMAN AD , Sweet K, Zhou XP, McLennan J, et al
    Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.
    J Clin Oncol. 2008;26:5393-400.
    PubMed     Text format     Related articles    Abstract available
    
    
    
24. MATULONIS UA , Horowitz NS, Campos SM, Lee H, et al
    Phase II Study of Carboplatin and Pemetrexed for the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer.
    J Clin Oncol. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
25. CHENG Z , Yin H, Du J, Yue X, et al
    Bilateral breast metastasis from small-cell carcinoma of the ovary.
    J Clin Oncol. 2008;26:5129-30.
    PubMed     Text format     Related articles   
    
    
    October 2008
26. TAN DS , Rothermundt C, Thomas K, Bancroft E, et al
    "BRCAness" Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated With BRCA1 and BRCA2 Mutations.
    J Clin Oncol. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
27. LEVANON K , Crum C, Drapkin R
    New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact.
    J Clin Oncol. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    September 2008
28. MORRIS PG , Swords R, Sukor S, Fortune A, et al
    Autoimmune Hemolytic Anemia Associated With Ovarian Cancer.
    J Clin Oncol. 2008.
    PubMed     Text format     Related articles   
    
    
    
29. LYNCH HT , Marcus JN, Rubinstein WS
    Stemming the tide of cancer for BRCA1/2 mutation carriers.
    J Clin Oncol. 2008;26:4239-43.
    PubMed     Text format     Related articles   
    
    
    
30. LUTGENDORF SK , Weinrib AZ, Penedo F, Russell D, et al
    Interleukin-6, Cortisol, and Depressive Symptoms in Ovarian Cancer Patients.
    J Clin Oncol. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
31. HAVRILESKY LJ , Secord AA, Darcy KM, Armstrong DK, et al
    Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
    J Clin Oncol. 2008;26:4144-50.
    PubMed     Text format     Related articles    Abstract available
    
    
    August 2008
32. AZAD NS , Posadas EM, Kwitkowski VE, Steinberg SM, et al
    Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
    J Clin Oncol. 2008;26:3709-14.
    PubMed     Text format     Related articles    Abstract available
    
    
    July 2008
33. KRIVAK TC , Darcy KM, Tian C, Armstrong D, et al
    Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.
    J Clin Oncol. 2008;26:3598-606.
    PubMed     Text format     Related articles    Abstract available
    
    
    
34. SCHILDER RJ , Sill MW, Lee RB, Shaw TJ, et al
    Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
    J Clin Oncol. 2008;26:3418-25.
    PubMed     Text format     Related articles    Abstract available
    
    
    
35. WEBERPALS JI , Clark-Knowles KV, Vanderhyden BC
    Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway.
    J Clin Oncol. 2008;26:3259-67.
    PubMed     Text format     Related articles    Abstract available
    
    
    
36. SEHOULI J , Stengel D, Oskay-Oezcelik G, Zeimet AG, et al
    Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.
    J Clin Oncol. 2008;26:3176-82.
    PubMed     Text format     Related articles    Abstract available
    
    
    June 2008
37. WALSH CS , Ogawa S, Karahashi H, Scoles DR, et al
    ERCC5 is a novel biomarker of ovarian cancer prognosis.
    J Clin Oncol. 2008;26:2952-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
38. GLINSKY GV
    "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management.
    J Clin Oncol. 2008;26:2846-53.
    PubMed     Text format     Related articles    Abstract available
    
    
    
39. FOTOPOULOU C , duBois A, Karavas AN, Trappe R, et al
    Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
    J Clin Oncol. 2008;26:2683-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
40. LHOMME C , Joly F, Walker JL, Lissoni AA, et al
    Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer.
    J Clin Oncol. 2008;26:2674-82.
    PubMed     Text format     Related articles    Abstract available
    
    
    
41. KAYE SB
    Reversal of drug resistance in ovarian cancer: where do we go from here?
    J Clin Oncol. 2008;26:2616-8.
    PubMed     Text format     Related articles   
    
    
    
42. GORIN I , Sastre-Garau X
    Strumal carcinoid tumor of the ovary.
    J Clin Oncol. 2008;26:2780-1.
    PubMed     Text format     Related articles   
    
    
    May 2008
43. ABOU-JAWDE RM , Oberoi SS
    Is single-agent chemotherapy acceptable in platinum-sensitive relapsed ovarian cancer?
    J Clin Oncol. 2008;26:2602-3.
    PubMed     Text format     Related articles   
    
    
    April 2008
44. VACH W , Bergmann TK, Brosen K
    No evidence for taxane/platinum pharmacogenetic markers: just lack of power?
    J Clin Oncol. 2008;26:1903-4.
    PubMed     Text format     Related articles   
    
    
    
45. PRAT A , Parera M, Del Campo JM
    Prognostic role of CA-125 nadir in stage IV epithelial ovarian cancer.
    J Clin Oncol. 2008;26:1771-2.
    PubMed     Text format     Related articles   
    
    
    
46. BRANFORD RA , Pantelidis P, Ross JR
    Ethnic considerations in pharmacogenetic studies.
    J Clin Oncol. 2008;26:1766-7.
    PubMed     Text format     Related articles   
    
    
    March 2008
47. GARFIELD DH
    Multitargeting ovarian epithelial cancer: adding the old to the new.
    J Clin Oncol. 2008;26:1565-6.
    PubMed     Text format     Related articles   
    
    
    
48. KAUFF ND , Domchek SM, Friebel TM, Robson ME, et al
    Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
    J Clin Oncol. 2008;26:1331-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
49. BAGGERLY KA , Coombes KR, Neeley ES
    Run batch effects potentially compromise the usefulness of genomic signatures for ovarian cancer.
    J Clin Oncol. 2008;26:1186-7.
    PubMed     Text format     Related articles   
    
    
    
50. RUDIN CM , Liu W, Desai A, Karrison T, et al
    Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
    J Clin Oncol. 2008;26:1119-27.
    PubMed     Text format     Related articles    Abstract available
    
    
    February 2008
51. FERRANDINA G , Ludovisi M, Lorusso D, Pignata S, et al
    Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.
    J Clin Oncol. 2008;26:890-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    January 2008
52. LANDEN CN JR , Birrer MJ, Sood AK
    Early Events in the Pathogenesis of Epithelial Ovarian Cancer.
    J Clin Oncol. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    
53. DOMCHEK S , Weber BL
    Genetic variants of uncertain significance: flies in the ointment.
    J Clin Oncol. 2008;26:16-7.
    PubMed     Text format     Related articles   
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: